Aqara Launches Its First Smart Wall Switch for Europe
22.6.2021 11:00:00 EEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first smart wall switch targeted for the European market, the Aqara Smart Wall Switch H1 EU. The Wall Switch H1 EU series is Aqara’s first smart wall switch supporting both round European wall boxes and 86 mm square wall boxes. It’s available in Single and Double Rocker versions, as well as in With Neutral and No Neutral versions. Along with the Wall Switch H1 EU, Aqara also introduced the latest Wireless Remote Switch H1 (Double Rocker) to the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005459/en/
Aqara Smart Wall Switch H1 EU and Aqara Wireless Switch H1 (Photo: Aqara)
Both the Wall Switch H1 EU and the Wireless Switch H1 support the Zigbee 3.0 protocol with better stability, compatibility, responsiveness and energy efficiency1. Both switches share the award-wining design with a metal frame, which makes the switches more rigid and durable. Moreover, the combination of the Wall Switch H1 EU and the Wireless Switch H1 can be used in a 2-way switch setup without excessive wiring, or to upgrade the existing 2-way setup to a smart one, so that users will be able to control the light or other device from two different places similar to using two hard-wired 2-way switches, or even from any part of the room by voice commands or via local automations.
The Wall Switch H1 EU is compatible with major smart home ecosystems and voice assistants, including Apple HomeKit, Amazon Alexa, Google Assistant, IFTTT, and more2. The availability of With Neutral and No Neutral versions makes it fit almost all homes, while the With Neutral version supports extra features such as power monitoring and overload protection. Other features of the Wall Switch H1 EU include:
- Convert to Wireless Switch Function: The button of the switch can be remapped so that you will get an extra “wireless switch” while the light or other device will be controlled by automations;
- Overheat Protection: Users can be ensured that their homes are safe and secure;
- LED Indicator Behavior Setting: Users can configure the LED indicator via the Aqara Home app, choosing to turn it off completely, turn it on when the switch is on, or vice versa3.
The Wireless Switch H1 is a HomeKit-compatible remote switch to control Aqara devices and other HomeKit accessories or to switch between smart home scenes. It comes with a double rocker, and recognizes 7 configurable actions including single click, double click, long press, and dual-button press. It also supports the High-Speed Click Mode, which reduces the response time down to 50 milliseconds4. The Wireless Switch H1 also features a 5-year battery life, the longest so far among all Aqara battery-powered devices.
The Wall Switch H1 EU and the Wireless Switch H1 are expected to be available in various European and Asian countries via authorized Aqara distributors in the following months. Please check with your regional distributor(s) for product availability.
For more details of the Wall Switch H1 EU and the Wireless Switch H1, please visit our website.
|
1 |
A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required. |
|
|
2 |
Integration with some third-party ecosystems may be unavailable by the time of the launch. |
|
|
3 |
Not all of these options are available for the No Neutral version. |
|
|
4 |
Only single clicks are recognized in the High-Speed Click Mode. |
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. We provide comprehensive smart home products and solutions that are beautifully designed, affordable and easy to use. Our products range from a variety of sensors to switches, curtain controllers, and door locks, and we have opened more than 400 Aqara Home stores globally to provide more personalized smart home solutions.
We continue to expand our global footprint in the United States, EU, Russia, Southeast Asia, Korea and China, and our online devices have covered 192 countries and territories, serving more than 2 million customers. We aspire to bring smart home technology to every household around the world.
For more information, please visit our website and follow our social platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005459/en/
Contact information
For Media Enquiry:
Michell Li
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
